Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.54 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 2/20 | 0.52 |
| ▸ | TSHR | P16473 | 3/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | ACKR3 | P25106 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22965254 | 0.81 | LMNA (0.48) | ALDH1A1SMN1; SMN2HDAC6MAPTTP53 | |
| SCHEMBL14847952 | 0.81 | MAPT (0.48) | ALDH1A1SMN1; SMN2USP2HDAC6MAPT | |
| SCHEMBL940950 | 0.78 | ALDH1A1 (0.37) | ALDH1A1MAPT | |
| SCHEMBL22965191 | 0.78 | PTGDR2 (0.47) | SMN1; SMN2MAPTTP53RECQLLMNA | |
| SCHEMBL30466612 | 0.76 | MAPT (0.70) | ALDH1A1SMN1; SMN2HDAC6MAPTTSHR | |
| SCHEMBL28366489 | 0.76 | MAPT (0.70) | ALDH1A1SMN1; SMN2HDAC6MAPTTSHR | |
| SCHEMBL38661375 | 0.76 | SMN1; SMN2 (0.45) | ALDH1A1SMN1; SMN2USP2HDAC6MAPT | |
| SCHEMBL31504944 | 0.75 | ACKR3 (0.53) | ALDH1A1USP2HDAC6TSHRACKR3 | |
| SCHEMBL5610013 | 0.75 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2USP2HDAC6MAPT | |
| SCHEMBL14685205 | 0.75 | SMN1; SMN2 (0.68) | ALDH1A1SMN1; SMN2USP2HDAC6MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020032187-A1 | Method for stimulating bone formation | SMITHKLINE BEECHAM CORPORATION | 2002-03-14 | — | — | US | disclosed |
| US-5977101-A | Benzimidazoles/Imidazoles Linked to a Fibrinogen Receptor Antagonist Template Having Vitronectin Receptor Antagonist Activity | SMITHKLINE BEECHAM CORPORATION (US) | 1999-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020032187-A1 | Method for stimulating bone formation | BMP2, BMP4, SOST | ALDH1A1 2599/4885SMN1; SMN2 3997/4885USP2 4418/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.